Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Mar;196(5):e47-e49.
doi: 10.1111/bjh.17929. Epub 2021 Nov 16.

Epidemiology of chronic lymphocytic leukaemia in an Irish subpopulation with total case ascertainment: an additional tool for health economic planning

Carmel Waldron  1 , David O'Brien  2 , Sarah Brophy  3 , Kanthi Perera  4 , Gerard M Crotty  4 , Eoghan Dunlea  4 , Aileen Walsh  4 , Michelle Connolly  4 , Ruth Clifford  5 , Hilary O'Leary  5 , Ashique Khan  5 , Greg Lee  1 , Emer Atkinson  6 , Giao Le  1 , Alexander Gillett  1 , Christopher L Bacon  1 , Anthony M McElligott  3 , Fiona Quinn  6 , Elisabeth Vandenberghe  1   6
Affiliations
Multicenter Study

Epidemiology of chronic lymphocytic leukaemia in an Irish subpopulation with total case ascertainment: an additional tool for health economic planning

Carmel Waldron et al. Br J Haematol. 2022 Mar.
No abstract available

Keywords: TP53; chronic lymphocytic leukaemia; epidemiology; incidence; targeted therapies.

PubMed Disclaimer

References

    1. SEER*explorer: an interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. 2021. Available from: http://seer.cancer.gov/explorer/
    1. National Cancer Registry Ireland. Cancer in Ireland 1994-2018 with estimates for 2018-2020: annual report of the National Cancer Registry. NCRI, Cork, Ireland. [Internet]. 2020. Available from: https://ncri.ie/data
    1. Scarfo L, Ferreri AJ, Ghia P. Chronic lymphocytic leukaemia. Crit Rev Oncol Hematol. 2016;104:169-82.
    1. Dreger P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M, et al. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood. 2018;132:892-902.
    1. Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:481-8.

LinkOut - more resources